Expert Interview
Discussing novel therapeutics to treat gastric cancer/GEJ Adenocarcinoma, with a focus Leap Therapeutics' DKN-01 (anti-DKK1) on top of PD-1 (tislelizumab) and chemotherapy in 1L GEA patients
Ticker(s): LPTXInstitution: MD Anderson
- Professor, Department of GI Medical Oncology at MD Anderson.
- Main interest is in GI oncology research, particularly focusing on gastric and esophagael cancers.
- Chair of Gastric Cancer and Esophagael Cancer Guidelines of the National Comprehensive Cancer Network for more than 25 years.
How do you currently treat gastric cancer?
Added By: wilson_adminWhat are your impressions of the data shown from DKN-01?
Added By: wilson_admin1. As DKN-01 is used in the triple- combination;
how confident are you that DKN-01 molecule is adding something on top of the PD-1 plus
chemo to produce these results?
From the pathophysiology of disease standpoint,
does it make sense to you that modulation of Dickkopf-1 activity synergizes
with PD-1+chemo? (e.g., how strong is the scientific rationale here, is there biology that we know of that makes reported
results logical)
Are there differences in response rates between stomach
and GEJ cancer with PD-1+ chemo regimen?
If you compare the results we have so far on
Claudin 18. 2, FGFR2b and a-DKK1 targeting agents – which data sets look most convincing
to you and why?
Epidemiology: % of patients expressing different
markers and overlaps – for Her2, Claudin 18, DKK1, FGFR2b
Based on what you know so far about DKN-01, what
would you say is your level of excitement on a 1 to 10 scale about this
product?
What else are you excited about in the Gastric/GEJ
cancer pipeline?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
